

# AZD4547

**Catalog No: tcsc0971**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g



## Specifications

---

**CAS No:**

1035270-39-3

**Formula:**

$C_{26}H_{33}N_5O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

FGFR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 300$  mg/mL (647.15 mM)

**Observed Molecular Weight:**

463.57


**Product Description**

AZD4547 is a potent inhibitor of the **FGFR** family with **IC<sub>50</sub>** of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.

IC50 & Target: IC50: 0.2 nM (FGFR1), 2.5 nM (FGFR2), 1.8 nM (FGFR3), 165 nM (FGFR4)<sup>[1]</sup>

**In Vitro:** AZD4547 also inhibits recombinant VEGFR2 (KDR) kinase activity with an IC<sub>50</sub> of 24 nM. In KG1a, Sum52-PE, MCF7, and KMS11 cell lines, AZD4547 potently inhibits autophosphorylation of FGFR1, 2, and 3 tyrosine kinases (IC<sub>50</sub> values of 12, 2, and 40 nM, respectively) and displays weaker inhibition of FGFR4 cellular kinase activity (IC<sub>50</sub>=142 nM). Significantly weaker inhibitory activity is observed versus cellular KDR and IGFR ligand-induced phosphorylation (IC<sub>50</sub> values of 258 and 828 nM, respectively), representing approximately 20- and 70-fold selectivity over cellular FGFR1. Besides, AZD4547 potently inhibits FGFR phosphorylation and downstream signaling affected through FRS2, PLCγ, and MAPK at the cellular level<sup>[1]</sup>.

**In Vivo:** Female SCID mice bearing KMS11 tumors are randomized and treated chronically with AZD4547 at a range of well-tolerated doses. Oral AZD4547 treatment results in dose-dependent tumor growth inhibition. Twice daily administration of AZD4547 at 3 mg/kg gives statistically significant tumor growth inhibition of 53% (P[1]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!